Trial Profile
Phase I Study of Lenalidomide and Conventional Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Dec 2020 Results (n=33) assessing safety and tolerability of this combination in patients with R/R AML and high risk MDS, published in the American Journal of Hematology
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.